Sartorius Aktiengesellschaft (BIT:1SRT)
Italy · Delayed Price · Currency is EUR | Market Cap | 13.86B -4.0% |
| Revenue (ttm) | 3.55B +3.2% |
| Net Income | 162.60M +70.1% |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | 85.23 |
| Forward PE | 34.82 |
| Dividend | 0.73 (0.47%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | n/a |
| Average Volume | 1 |
| Open | n/a |
| Previous Close | 177.60 |
| Day's Range | n/a |
| 52-Week Range | 147.80 - 209.50 |
| Beta | n/a |
| RSI | 50.93 |
| Earnings Date | Apr 23, 2026 |
About BIT:1SRT
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture... [Read more]
Financial Performance
In 2025, BIT:1SRT's revenue was 3.54 billion, an increase of 4.66% compared to the previous year's 3.38 billion. Earnings were 154.90 million, an increase of 84.40%.
Financial StatementsNews
EQS-DD: Sartorius AG: Dr. Alexandra Gatzemeyer, Acquisition of 5,203 ordinary shares as a share‑based compensation component upon fulfillment of the relevant contractual condition.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 06.05.2026 / 14:20 CET/CEST The issuer is solely responsi...
EQS-DD: Sartorius AG: Dr. Alexandra Gatzemeyer, Acquisition of 4,268 preferrence shares as a share‑based compensation component upon fulfillment of the relevant contractual condition.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 06.05.2026 / 14:15 CET/CEST The issuer is solely responsi...
Sartorius AG (SSSGY) Q1 2026 Earnings Call Highlights: Strong Start with Robust Sales Growth ...
Sartorius AG (SSSGY) Q1 2026 Earnings Call Highlights: Strong Start with Robust Sales Growth and Strategic Innovations
Q1 2026 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Q1 2026 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Sartorius Aktiengesellschaft Earnings Call Transcript: Q1 2026
Sales and recurring business grew strongly in Q1 2026, with EBITDA margin resilient and cash flow up. Guidance for 2026 is confirmed, expecting 5%-9% sales growth and continued deleveraging, despite FX and geopolitical risks.
Sartorius Aktiengesellschaft (SARTF) Reports Q1 Earnings with Positive Outlook
Sartorius Aktiengesellschaft (SARTF) Reports Q1 Earnings with Positive Outlook
Sartorius AG Q1 Sales Increase
BRUSSELS (dpa-AFX) - Sartorius AG (SARTF) revealed earnings for first quarter of EUR56.2 millionThe company's bottom line came in at EUR56.2 million, or EUR1.20 per share. This compares with EUR48...
Sartorius Q1 Underlying Net Profit Declines; Confirms 2026 Guidance
(RTTNews) - Sartorius (SRT3.DE, SRT.DE) reported first quarter net profit of 56.2 million euros compared to 48.5 million euros, prior year. Underlying EBITDA was up slightly by 1.6 percent to 267 mill...
Sartorius Aktiengesellschaft Transcript: AGM 2026
AGM highlighted strong 2025 financial results, strategic acquisitions, and investments in innovation and sustainability. Leadership changes and refined strategy focus on portfolio, customer experience, and operational excellence. Dividend of EUR 0.73/0.74 per share proposed.
Sartorius Aktiengesellschaft Transcript: CMD 2026
Ambitious midterm targets include 8%-11% organic revenue growth and 50-75 bps annual EBITDA margin expansion, driven by innovation in single-use technologies, AI, and advanced therapies. Strategic investments in global capacity, digitalization, and customer experience underpin resilience and future growth.
Sartorius Aktiengesellschaft Earnings Call Transcript: Q4 2025
2025 saw strong recurring revenue growth, margin expansion, and improved leverage, with results exceeding guidance. 2026 guidance anticipates 5%-9% sales growth, margin above 30%, and continued investment in innovation and capacity, amid ongoing market normalization and volatility.
It's time to scoop up undervalued stocks in this critical sector of the economy
Expanding your horizons and considering neglected sectors can help you identify bargain opportunities while defending your investment portfolio from a stock-market decline.
Sartorius Aktiengesellschaft Earnings Call Transcript: Q3 2025
Sales grew 7.5% in constant currencies, led by strong consumables demand and margin expansion. Guidance for 2025 was specified, with group sales expected to rise 7% and EBITDA margin above 29.5%. Equipment demand remains subdued, but gradual recovery is anticipated.
Sartorius Shares Rise After Guidance Lift
Sartorius said it now expects 7% revenue growth for 2025, compared with 6% previously, as underlying net profit rose 17%.
Sartorius Aktiengesellschaft Earnings Call Transcript: Q2 2025
H1 2025 delivered 6% revenue growth and 12% EBITDA growth, led by strong consumables demand, while equipment sales lagged. Guidance for 2025 is confirmed, with continued margin expansion and deleveraging, despite FX and tariff headwinds.
Sartorius Aktiengesellschaft Earnings Call Transcript: Q1 2025
Q1 2025 delivered strong sales and margin growth, led by consumables, while equipment demand stayed soft. Guidance for 2025 is robust, with 6% sales growth and 29%-30% EBITDA margin targeted. The MatTek acquisition and regulatory shifts support innovation and future growth.
Sartorius Aktiengesellschaft Transcript: AGM 2025
The AGM highlighted stable revenues, strong order growth, and continued profitability despite market volatility. Leadership transitions were announced, with a new CEO set for July 2025. Strategic investments, innovation, and sustainability remain key priorities.
Sartorius Aktiengesellschaft Earnings Call Transcript: Q4 2024
2024 results met revised guidance with robust profitability and strong order intake in consumables, while equipment sales remained weak. Free cash flow doubled, leverage improved, and 2025 is expected to bring moderate, profitable growth above market rates, with continued focus on efficiency and deleveraging.
Betting on Growth: 4 Favorite Stocks From T. Rowe Price's Peter Bates
The manager of the Global Select Equity Strategy looks for high margins, cash generation, competitive advantages, and a long runway of growth.
Sartorius Aktiengesellschaft Earnings Call Transcript: Q3 2024
Nine-month 2024 results met expectations, with robust recurring sales and strong order intake, especially in consumables, offsetting weak equipment demand. Profitability and cash flow improved, guidance for the year is confirmed, and efficiency programs are set to deliver further benefits in Q4.
Sartorius Aktiengesellschaft Earnings Call Transcript: Q2 2024
H1 results met targets but sales and margins declined year-over-year amid ongoing market volatility and weak demand, especially for equipment. Guidance for 2024 was lowered to flat sales with a focus on efficiency gains, while long-term fundamentals remain positive.